Developer docs
API playgroundTry for free, no card

Search company profiles

Sigmovir Biosystems

Full company profile

uuid0008hcc

Namestring
Sigmovir Biosystems
Legal namestring
Sigmovir Biosystems, Inc.
Websiteurl
sigmovir.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Sigmovir Biosystems, Inc. (SBI) is a privately held Maryland-based biotechnology company operating as a specialty preclinical contract research organization (CRO) centered on the cotton rat (Sigmodon genus) model of human infectious disease. The cotton rat is uniquely permissive to a wide range of human pathogens — including RSV, hMPV, influenza, parainfluenza, adenovirus, measles, HSV, and bacterial agents such as Staphylococcus, Streptococcus, and Mycobacterium tuberculosis — and possesses fully functional Mx genes that respond to infection similarly to human Mx genes, unlike common laboratory mouse strains. SBI's scientists have cloned over 300 cotton rat genes (deposited in GenBank), developed 50+ cotton rat reagents, and produced 50+ peer-reviewed publications (20+ in the last five years), and the company maintains one of the world's largest colonies of inbred cotton rats under AAALAC-accredited husbandry.

The company monetizes this platform through two primary streams: (1) contract research services for academic and commercial clients, covering quantitative virology, histopathology, serology/immunology, molecular diagnostics of viral infections, mucosal immune response evaluation, in vitro screening, and adjuvant delivery / adenovirus-based vector therapy development, with a focus on vaccines and anti-infective agents for respiratory viruses and HSV; and (2) direct sales of cotton rats to commercial and academic institutions for off-site studies. Distribution is entirely domestic through direct B2B channels, with sales and contract-service inquiries routed through a single named commercial lead (Kevin C. Yim) and scientific inquiries handled by the CEO/scientific leadership (Marina Boukhvalova, Jorge Blanco). The model is the de facto "gold standard" for RSV — the FDA relied on cotton rat preclinical data alone to consent clinical trials for RespiGam and Synagis, the latter of which reduced RSV hospitalization in high-risk infants by up to 80%.

SBI is a small organization (1–10 employees) with no disclosed funding rounds, no public revenue, and no named institutional investors. Its strategic posture is that of a niche, scientifically entrenched CRO whose growth lever is depth of platform (transgenic model development, gene/reagent expansion, new service adjacencies) rather than headcount or geographic expansion.

Short descriptiontext

Sigmovir Biosystems is a Rockville, MD-based preclinical CRO specializing in the cotton rat (Sigmodon) model of human infectious diseases, offering contract research services, laboratory assays, and live cotton rat sales to academic and commercial biotech and pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, preclinical animal models, infectious disease research, cotton rat model, vaccine development services
Industry1 code
PRIMARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research (Infectious Disease / Animal Models)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Provides pre-clinical research services using the cotton rat model for academic and commercial clients. Services include quantitative virology, histopathology, serology/immunology, molecular diagnostics, and vaccine/therapeutic testing. Revenue generated through project-based contract work.

sigmovir.com
2Cotton Rat Sales
TypeHardware Sales
Description

Sales of cotton rats to commercial and academic institutions for off-site research studies. The company maintains one of the largest colonies of inbred cotton rats in the world.

sigmovir.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sigmovir Biosystems provides contract preclinical research services using the cotton rat (Sigmodon) animal model for human infectious diseases, including validated models for RSV, hMPV, Influenza, Parainfluenza, Adenovirus, HSV-1, and Measles, along with laboratory services such as quantitative virology, histopathology, serology/immunology, molecular diagnostics, and mucosal immune response evaluation. The company also develops adjuvant delivery systems and adenovirus-based vector therapies, and sells inbred cotton rats from one of the world's largest colonies to external academic and commercial researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Synagis decreased hospitalization rate of high-risk infants by up to 80% in clinical trials consented by FDA based solely on cotton rat preclinical data
+1 more record
Product overview1 text field

Sigmovir Biosystems is a Maryland-based biotechnology company offering a unified portfolio of contract research services centered around the cotton rat model of human infectious diseases. The core offerings include infectious disease models (RSV, hMPV, Influenza, Para-Influenza, Adenovirus, HSV, and Measles), laboratory research services (Quantitative Virology, Histopathology, Serology, Molecular Diagnostics), and direct sale of cotton rats for off-site research. Additional services include development of adjuvant delivery systems and adenovirus-based vector therapies. The company leverages over 100 years of combined experience in the cotton rat model and has developed over 300 cotton rat gene clones to support preclinical drug discovery and vaccine development.

Product and service6 records
1Cotton Rat Model Contract Research Services
CategoryContract Research Services
Description

Project-based contract research using the cotton rat model to test vaccines, anti-infective agents, and therapeutics for human infectious diseases. Targeted at academic institutions and commercial biotech and pharmaceutical groups.

2Preclinical Infectious Disease Models
CategoryPreclinical Animal Models
Description

Validated cotton rat models for RSV, hMPV, Influenza, Para-Influenza type 3, Human Adenovirus, Herpes Simplex Virus type 1, and Measles virus offered as preclinical platforms to clients.

3Laboratory Research Services
CategoryLaboratory Services
Description

Supporting laboratory services including quantitative virology, histopathology, serology/immunology, molecular diagnostics of viral infections, molecular analysis of inflammatory and immune responses, mucosal immune response evaluation, and in vitro screening.

4Cotton Rats for Off-Site Research
CategoryResearch Animals
Description

Sale of inbred cotton rats of various ages to commercial and academic institutions for off-site research, sourced from one of the largest inbred cotton rat colonies in the world.

5Adjuvant Delivery Systems Development
CategoryVaccine Development Services
Description

Development of adjuvant delivery systems to support vaccine research programs using the cotton rat model.

6Adenovirus-Based Vector Therapy Development
CategoryGene Therapy Development Services
Description

Development of adenovirus-based vector therapy for gene delivery applications using the cotton rat model.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Non-profit provider of high-quality laboratory mice and research services, including preclinical model development and in vivo pharmacology. Comparable to Sigmovir in offering specialized animal model infrastructure plus associated research services to pharma/biotech clients.

TypeBroad incumbent
Description

Large-scale preclinical CRO with extensive animal model and in vivo research services for vaccine and therapeutic developers. Relevant as a broad incumbent that competes for similar contract research budgets, though not specialized in the cotton rat.

TypeDirect peer
Description

Supplier of genetically engineered rodent models and research services for drug discovery. Directly comparable to Sigmovir's cotton rat sales + contract research revenue model, including breeding of specialized rodent lines for academic/commercial buyers.

TypeDirect peer
Description

Specialty breeder and supplier of purpose-bred laboratory animals (including ferrets used in respiratory virus research) plus research services. Closely comparable model of monetizing a difficult-to-breed animal line plus associated preclinical services.

TypeBroad incumbent
Description

Preclinical CRO offering research models, animal health products, and contract research services for drug development. Overlaps with Sigmovir in the animal-model-based contract research segment but at broader scale and scope.

TypeBroad incumbent
Description

Global CRO with extensive preclinical and clinical development services including animal model studies. Represents an incumbent alternative that vaccine sponsors may choose for one-stop-shop CRO needs versus Sigmovir's niche specialization.

TypeBroad incumbent
Description

Integrated CRO providing drug discovery and preclinical development services globally. Comparable as a competing CRO option for vaccine and infectious disease sponsors evaluating outsourced preclinical research partners.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical research capabilities including animal model studies. Represents a large-scale alternative for vaccine developers seeking outsourced preclinical research, though focused on broader service portfolio.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sigmovir Biosystems

Preclinical Contract Research (Infectious Disease / Animal Models)sigmovir.com

Sigmovir Biosystems is a Rockville, MD-based preclinical CRO specializing in the cotton rat (Sigmodon) model of human infectious diseases, offering contract research services, laboratory assays, and live cotton rat sales to academic and commercial biotech and pharmaceutical clients.

What Sigmovir Biosystems does

Sigmovir Biosystems, Inc. (SBI) is a privately held Maryland-based biotechnology company operating as a specialty preclinical contract research organization (CRO) centered on the cotton rat (Sigmodon genus) model of human infectious disease. The cotton rat is uniquely permissive to a wide range of human pathogens — including RSV, hMPV, influenza, parainfluenza, adenovirus, measles, HSV, and bacterial agents such as Staphylococcus, Streptococcus, and Mycobacterium tuberculosis — and possesses fully functional Mx genes that respond to infection similarly to human Mx genes, unlike common laboratory mouse strains. SBI's scientists have cloned over 300 cotton rat genes (deposited in GenBank), developed 50+ cotton rat reagents, and produced 50+ peer-reviewed publications (20+ in the last five years), and the company maintains one of the world's largest colonies of inbred cotton rats under AAALAC-accredited husbandry.

The company monetizes this platform through two primary streams: (1) contract research services for academic and commercial clients, covering quantitative virology, histopathology, serology/immunology, molecular diagnostics of viral infections, mucosal immune response evaluation, in vitro screening, and adjuvant delivery / adenovirus-based vector therapy development, with a focus on vaccines and anti-infective agents for respiratory viruses and HSV; and (2) direct sales of cotton rats to commercial and academic institutions for off-site studies. Distribution is entirely domestic through direct B2B channels, with sales and contract-service inquiries routed through a single named commercial lead (Kevin C. Yim) and scientific inquiries handled by the CEO/scientific leadership (Marina Boukhvalova, Jorge Blanco). The model is the de facto "gold standard" for RSV — the FDA relied on cotton rat preclinical data alone to consent clinical trials for RespiGam and Synagis, the latter of which reduced RSV hospitalization in high-risk infants by up to 80%.

SBI is a small organization (1–10 employees) with no disclosed funding rounds, no public revenue, and no named institutional investors. Its strategic posture is that of a niche, scientifically entrenched CRO whose growth lever is depth of platform (transgenic model development, gene/reagent expansion, new service adjacencies) rather than headcount or geographic expansion.

Sigmovir Biosystems firmographics

Firmographics
Name
Sigmovir Biosystems
Legal name
Sigmovir Biosystems, Inc.
Website
https://sigmovir.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Sigmovir Biosystems is a Rockville, MD-based preclinical CRO specializing in the cotton rat (Sigmodon) model of human infectious diseases, offering contract research services, laboratory assays, and live cotton rat sales to academic and commercial biotech and pharmaceutical clients.
Ownership category
akta.pro rank

Sigmovir Biosystems industry classification

Industry
Product category
Preclinical Contract Research (Infectious Disease / Animal Models)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Keywords

  • Contract research services
  • Preclinical animal models
  • Infectious disease research
  • Cotton rat model
  • Vaccine development services

Where Sigmovir Biosystems is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sigmovir Biosystems business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Provides pre-clinical research services using the cotton rat model for academic and commercial clients. Services include quantitative virology, histopathology, serology/immunology, molecular diagnostics, and vaccine/therapeutic testing. Revenue generated through project-based contract work.
  2. Cotton Rat Sales: Sales of cotton rats to commercial and academic institutions for off-site research studies. The company maintains one of the largest colonies of inbred cotton rats in the world.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Sigmovir Biosystems product offering

Product offering

Core offering

Sigmovir Biosystems provides contract preclinical research services using the cotton rat (Sigmodon) animal model for human infectious diseases, including validated models for RSV, hMPV, Influenza, Parainfluenza, Adenovirus, HSV-1, and Measles, along with laboratory services such as quantitative virology, histopathology, serology/immunology, molecular diagnostics, and mucosal immune response evaluation. The company also develops adjuvant delivery systems and adenovirus-based vector therapies, and sells inbred cotton rats from one of the world's largest colonies to external academic and commercial researchers.

Product overview

Sigmovir Biosystems is a Maryland-based biotechnology company offering a unified portfolio of contract research services centered around the cotton rat model of human infectious diseases. The core offerings include infectious disease models (RSV, hMPV, Influenza, Para-Influenza, Adenovirus, HSV, and Measles), laboratory research services (Quantitative Virology, Histopathology, Serology, Molecular Diagnostics), and direct sale of cotton rats for off-site research. Additional services include development of adjuvant delivery systems and adenovirus-based vector therapies. The company leverages over 100 years of combined experience in the cotton rat model and has developed over 300 cotton rat gene clones to support preclinical drug discovery and vaccine development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cotton Rat Model Contract Research Services Project-based contract research using the cotton rat model to test vaccines, anti-infective agents, and therapeutics for human infectious diseases. Targeted at academic institutions and commercial biotech and pharmaceutical groups.
  • Preclinical Infectious Disease Models Validated cotton rat models for RSV, hMPV, Influenza, Para-Influenza type 3, Human Adenovirus, Herpes Simplex Virus type 1, and Measles virus offered as preclinical platforms to clients.
  • Laboratory Research Services Supporting laboratory services including quantitative virology, histopathology, serology/immunology, molecular diagnostics of viral infections, molecular analysis of inflammatory and immune responses, mucosal immune response evaluation, and in vitro screening.
  • Cotton Rats for Off-Site Research Sale of inbred cotton rats of various ages to commercial and academic institutions for off-site research, sourced from one of the largest inbred cotton rat colonies in the world.
  • Adjuvant Delivery Systems Development Development of adjuvant delivery systems to support vaccine research programs using the cotton rat model.
  • Adenovirus-Based Vector Therapy Development Development of adenovirus-based vector therapy for gene delivery applications using the cotton rat model.

Quantifiable outcome

  • Synagis decreased hospitalization rate of high-risk infants by up to 80% in clinical trials consented by FDA based solely on cotton rat preclinical data
  • +1 more outcomes

Companies that use Sigmovir Biosystems

Customer profile

Segments2 records

Ideal customer profiles2 records

Sigmovir Biosystems technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sigmovir Biosystems partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Sigmovir Biosystems competitors and assessment

Company assessment

Direct peers

  • Jackson Laboratory: Non-profit provider of high-quality laboratory mice and research services, including preclinical model development and in vivo pharmacology. Comparable to Sigmovir in offering specialized animal model infrastructure plus associated research services to pharma/biotech clients.
  • Taconic Biosciences: Supplier of genetically engineered rodent models and research services for drug discovery. Directly comparable to Sigmovir's cotton rat sales + contract research revenue model, including breeding of specialized rodent lines for academic/commercial buyers.
  • Marshall BioResources: Specialty breeder and supplier of purpose-bred laboratory animals (including ferrets used in respiratory virus research) plus research services. Closely comparable model of monetizing a difficult-to-breed animal line plus associated preclinical services.

Broad incumbents

  • Charles River Laboratories: Large-scale preclinical CRO with extensive animal model and in vivo research services for vaccine and therapeutic developers. Relevant as a broad incumbent that competes for similar contract research budgets, though not specialized in the cotton rat.
  • Inotiv: Preclinical CRO offering research models, animal health products, and contract research services for drug development. Overlaps with Sigmovir in the animal-model-based contract research segment but at broader scale and scope.
  • Labcorp Drug Development (Covance): Global CRO with extensive preclinical and clinical development services including animal model studies. Represents an incumbent alternative that vaccine sponsors may choose for one-stop-shop CRO needs versus Sigmovir's niche specialization.
  • Pharmaron: Integrated CRO providing drug discovery and preclinical development services globally. Comparable as a competing CRO option for vaccine and infectious disease sponsors evaluating outsourced preclinical research partners.
  • WuXi AppTec: Global CRO/CDMO with preclinical research capabilities including animal model studies. Represents a large-scale alternative for vaccine developers seeking outsourced preclinical research, though focused on broader service portfolio.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Sigmovir Biosystems social profiles

Digital presence

Sigmovir Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sigmovir Biosystems leadership team

Management profile

Number of profiles

Profiles3 records

Sigmovir Biosystems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sigmovir Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sigmovir Biosystems

What does Sigmovir Biosystems do?

Sigmovir Biosystems provides contract preclinical research services using the cotton rat (Sigmodon) animal model for human infectious diseases, including validated models for RSV, hMPV, Influenza, Parainfluenza, Adenovirus, HSV-1, and Measles, along with laboratory services such as quantitative virology, histopathology, serology/immunology, molecular diagnostics, and mucosal immune response evaluation. The company also develops adjuvant delivery systems and adenovirus-based vector therapies, and sells inbred cotton rats from one of the world's largest colonies to external academic and commercial researchers.

Is Sigmovir Biosystems a public or private company?

Sigmovir Biosystems is a private company. It is classified as unknown and is currently operating.

When was Sigmovir Biosystems founded?

Sigmovir Biosystems was founded in -1. It employs 11 to 50 people.

Where is Sigmovir Biosystems based?

Sigmovir Biosystems is headquartered in Rockville, United States, in the North America region.

How does Sigmovir Biosystems make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are cotton Rat Sales.

Who are Sigmovir Biosystems's main competitors?

Direct peers on record are Jackson Laboratory, Taconic Biosciences and Marshall BioResources. Broad incumbents are Charles River Laboratories, Inotiv, Labcorp Drug Development (Covance), Pharmaron and WuXi AppTec.

Does Sigmovir Biosystems have an API?

No public API is recorded for Sigmovir Biosystems.

What industry is Sigmovir Biosystems in?

Sigmovir Biosystems's product category is Preclinical Contract Research (Infectious Disease / Animal Models). Its primary akta.pro industry code is HLAMAKAM, Vaccine R&D, Clinical/Field Trials & Regulatory Affairs. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales